Volume 3, Issue 8
Editorialp. 703
Stem cell clinical trials: toward cell-based therapy for retinal degenerations
Author(s): Henry Klassen
Editorialp. 707
Is there a future for FabI inhibitors as antibacterial agents?
Author(s): AW Karchmer, B Hafkin
Editorialp. 711
Nocturia, of clinical importance
Author(s): Jennifer G Rothschild, David J Osborn, Melissa R Kaufman , Roger R Dmochowski
Editorialp. 715
Development of a cross-pharmaceutical database: a paradigm change for accelerating the drug-development process
Author(s): Larry Alphsclinical trials , database , drug development ,neuropsychiatric ,pharmaceutical
Expert Reviewp. 23–27
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
Clinical Trail Prospectivep. 731
Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis
Author(s): Michael W Konstan, Drucy Borowitz, Nicole Mayer-Hamblett, Carlos Milla, Leslie Hendeles, Susan Murray, Richard A Kronmal, Susan Casey, Lynn M Rose, Wayne J Morgan,Bonnie W Ramsey
Therapeutic Prospectivep. 743
Chloroquine enjoys a renaissance as an antineoplastic therapy
Author(s): Virginia Espina, Lance A Liotta
Review: Clinical Trail Outcomesp. 763
Tesamorelin for the treatment of excess abdominal fat in HIV-infected individuals with lipodystrophy
Author(s): G Guaraldi, C Stentarelli,J Faluz
Clinical Trail Methodologyp. 777
BRCA status in epithelial ovarian cancer: implications for management and future clinical trial design
Author(s): Panagiotis A Konstantinopoulos , Ursula A Matulonis
Clinical Trail Methodologyp. 791
Assessment methodologies in sleep medicine clinical trials
Author(s): Elena A Wood,W Vaughn McCall
Acknowledgementsp. 801
